Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $29.05M | $32.71M | $61.28M | $55.29M | $23.80M | $67.69M |
| Cost of Revenue | $911.00K | $1.60M | $13.13M | $8.97M | $2.06M | $1.13M |
| Gross Profit | $28.14M | $31.11M | $48.15M | $46.32M | $21.74M | $66.56M |
| Gross Margin | 96.86% | 95.11% | 78.58% | 83.78% | 91.36% | 98.33% |
| Operating Expenses | $1.03B | $-4.47B | $1.22B | $1.40B | $1.09B | $598.98M |
| Operating Income | $-1.00B | $4.50B | $-1.18B | $-1.35B | $-1.07B | $-532.42M |
| Operating Margin | -3453.32% | 13746.93% | -1917.95% | -2444.82% | -4500.52% | -786.58% |
| Net Income | $-171.98M | $4.35B | $-1.01B | $-845.26M | $-809.23M | $1.20B |
| Net Margin | -591.96% | 13294.18% | -1646.59% | -1528.89% | -3400.86% | 1773.57% |
| EPS (Basic) | $-0.24 | $5.55 | $-1.42 | $-1.26 | $-1.18 | $1.75 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A |